Methods, devices, and systems may use a kinetic model to determine physiological parameters related to the kinetics of red blood cell glycation, elimination, and generation. Such physiological parameters can be used, for example, to determine a more reliable calculated HbA1c. In another example, a method may comprise: receiving a plurality of glucose levels over a time period; receiving a glycated hemoglobin (HbA1c) level corresponding to an end of the time period; determining at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k.sub.gly), a red blood cell generation rate constant (k.sub.gen), a red blood cell elimination constant (k.sub.age), and an apparent glycation constant (K), based on (1) the plurality of glucose levels and (2) the HbA1c level; and adjusting a glucose level target based on the at least one physiological parameter.

A control section as a tissue identification device includes: an absorbance ratio calculating section configured to calculate the ratio of an absorbance indicated by a transmitted portion of first inspection light transmitted through biological tissue to an absorbance indicated by a transmitted portion of second inspection light transmitted through the biological tissue; and an identification information generating section configured to generate identification information indicative of the type or state of the biological tissue by determining within which of a plurality of preset numerical ranges the ratio falls.

This invention is in the field of medical devices. Specifically, the present invention provides fluidic systems having a plurality of reaction sites surrounded by optical barriers to reduce the amount of optical cross-talk between signals detected from various reaction sites. The invention also provides a method of manufacturing fluidic systems and methods of using the systems.

Devices, systems, and methods for removing targeted lesions from vessels. In at least one embodiment of a device for removing a stenotic lesion from a vessel, the device comprises a sizing portion capable of measuring a luminal size parameter when at least part of the device is positioned within a lumen of a luminal organ, a typing portion, wherein at least part of the at least one typing portion is capable of physically touching a portion of the luminal organ or a structure therein, and a treatment portion capable of removing at least part of a stenotic lesion from the luminal organ.

Under one aspect, an apparatus for analyzing the skin of a subject includes a hyperspectral sensor for obtaining a hyperspectral image of the subject. The apparatus further includes a control computer that is in electronic communication with the hyperspectral sensor and which controls at least one operating parameter of the hyperspectral sensor. The control computer includes a processor unit and a computer readable memory. The memory includes executable instructions for controlling the at least one operating parameter of the hyperspectral sensor. The memory includes executable instructions for applying a wavelength dependent spectral calibration standard constructed for the hyperspectral sensor to a hyperspectral image collected by the hyperspectral sensor. The apparatus further includes a light source that illuminates the skin of the subject for the hyperspectral sensor.

A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (k.sub.age) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (k.sub.gly), a red blood cell generation rate constant (k.sub.gen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the k.sub.age. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.

Oncology monitoring systems include: (a) a first plurality of radiation sensors configured to reside proximate a target tumor treatment site of a patient, the sensors being configured to provide radiation data associated with the tumor treatment site; and (b) a first portable receiver in communication with the plurality of sensors. The receiver is configured to obtain radiation data from the sensors at a plurality of different times. The receiver is in communication with a local and/or remote computer that tracks variation in the radiation data to provide dynamic tumor site information.

The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.

Accurately quantifying optical absorption coefficient using acoustic spectra of photoacoustic signals. Optical absorption is closely associated with many physiological parameters, such as the concentration and oxygen saturation of hemoglobin, and it can be used to quantify the concentrations of non-fluorescent molecules. A sample is illuminated by, for example, a pulsed laser and following the absorption of optical energy, a photoacoustic pressure is generated via thermo-elastic expansion. The acoustic waves then propagate and are detected by a transducer. The optical absorption coefficient of the sample is quantified from spectra of the measured photoacoustic signals. Factors, such as system bandwidth and acoustic attenuation, may affect the quantification but are canceled by dividing the acoustic spectra measured at multiple optical wavelengths.

The present invention generally relates to systems and methods for delivering and/or receiving a substance or substances such as blood, from subjects, e.g., from the skin and/or from other tissues of the body. In some cases, the device may contain a substance transfer component such as needles or microneedles, which can be inserted into the skin or another organ to deliver and/or receiving fluid or other substances from the subject. In some embodiments, the device may include an activator constructed and arranged to insert one or more substance transfer components into the skin or other organ. In certain cases, the device may also include a storage chamber for receiving a fluid received from the subject.